GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate safety and pharmacokinetic of GP2013 in Japanese patients with CD20 positive low tumor burden indolent B-cell NHL under weekly dosing schedule.
Indolent B-cell Non-Hodgkin's Lymphoma
DRUG: GP2013
To evaluate safety of GP2013, Adverse events, laboratory abnormalities, 12 weeks|Area under the curve calculated from start of dose to the end of the dosing interval (tau) of GP2013, 12 weeks|Maximum observed concentration of GP2013, 12 weeks|Time to reach maximum concentration of GP2013, 12 weeks|Minimum (trough) observed concentration during each dosing interval of GP2013, 12 weeks|Terminal elimination rate constant calculated as the slope of the linear regression of the terminal phase of the logarithmic concentration-time profile of GP2013, 12 weeks|Elimination half-life associated with the terminal slope of GP2013, 12 weeks
To evaluate efficacy of GP2013, Antitumor activity, 12 weeks|To evaluate the incidence of immunogenicity (ADA formation) against GP2013, Immunogenicity (ADA formation), 12 weeks|To evaluate peripheral CD19+ B-cell count, CD19 + B-cell count, 12 weeks
The purpose of this study is to evaluate safety and pharmacokinetic of GP2013 in Japanese patients with CD20 positive low tumor burden indolent B-cell NHL under weekly dosing schedule.